Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod in elderly UC
NCT07243639Recruiting
- Sponsor
- Showa Inan General Hospital
- Start
- Oct 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of etrasimod in ulcerative colitis (UC), sponsored by Showa Inan General Hospital. Primary endpoint: Clinical Remission Rate at 4 weeks. Started Oct 2025; status: recruiting.
02
Drugs
etrasimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07243639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07243639.